1. The metabolism of some vasoactive hormones perfused through pulmonary vessels was studied in samples of human lung obtained at operations.
Introduction
The pharmacokinetic function of lung, i.e. the ability of the lung to alter the biological activity of a substrate as it passes through the pulmonary circulation, was first systematically studied in animals in uivo (Vane, 1969) . Analogous investigations with human lung in uivo (Gillis, Greene, Cronau & Hammond, 1972; Jose, Niederhauser Smith, 1976) are possible though clearly more difficult to perform. We have therefore used samples of human lung (removed during surgical operations) perfused via the pulmonary vessels to investigate further some aspects of the pharmacokinetic function of this organ. Some of these results have been communicated to the Physiological Society (Al-Ubaidi & Bakhle, 1979a) .
Methods

Preparation of lung
Small pieces of peripheral lung (about 10-15 g) removed during surgical operations for lung cancer, were transported to the laboratory covered with paper towels, wet with Krebs solution, at room temperature. The pieces, which were covered with pleura, were normal in appearance and had only one cut surface. A blood vessel in the cut surface was cannulated and perfused with heparinized Krebs solution (20 ml) from a syringe. If within a few seconds, blood and then perfusate emerged from another vessel on the surface, perfusion was continued with plain Krebs solution from the pump. If this did not happen, other vessels were cannulated and tested similarly. The perfused part of the lung was often visible as a pale, bloodless area in contrast to the darker, unperfused tissue.
Lung was perfused for 20 min to wash out blood and any accumulated drugs before beginning the experiment. A maximum of 90 min total perfusion time was permitted for each experiment, although many experiments were completed in less time. In preliminary experiments, the inactivation of 5-hydioxytryptamine and prostaglandin E, measured by bioassay was found to be constant over this , F. AI-Ubaidi and Y. S. Bakhle experimental period. The perfusion solution [Krebs bicarbonate of the following composition (mmol/l): NaHCO,, 25; NaCI, 120; KCI, 4.7; CaCI,, 2.5; KH,PO,, 1.2; MgSO,, 1.2; glucose, 5-61 was pumped at a constant rate of 8 ml/min and was warmed to 37OC and gassed with O,/CO, (95 : 5).
In general each patient provided one piece of lung and only one substrate was studied in each piece. In a few cases a lung sample provided two perfused pieces and each piece was used with a different substrate.
Bioassay
EfRuent from the lung superfused a number of isolated tissues for bioassay (Vane, 1964) . The assay tissues used were: for 5-hydroxytryptamine and prostaglandin E,, rat stomach strip; for products of arachidonic acid metabolism, rat stomach strip, rabbit aorta and rat colon. In experiments involving prostaglandin E, or arachidonic acid metabolism, to increase specificity for prostaglandin E, and to prevent endogenous metabolism of arachidonic acid, the assay tissues were superfused (0.1 ml/min) with a mixture of antagonists (final concentrations; mepyramine 350 nmol/l, hyoscine 330 nmol/l, phenoxybenzamine 330 nmol/l, propranolol 7 pmol/l, methysergide 560 nmol/l and indomethacin 2.8 pmol/l: Eckenfels & Vane, 1972) . In some of the latter experiments two sets of assay tissues were used separated by a glass coil to provide a 1 min delay circuit (Alabaster & Hawkeswood, 1978) . After the initial 20 min perfusion the lung emuent was directed over the assay tissues, previously superfused with plain Krebs solution. When the tissues had equilibrated (10-15 min). their responses to agonist injected directly were determined and compared with those to agonist injected into the cannula in the pulmonary vessel and thus passing through the pulmonary vasculature before reaching the assay tissue. Thus, if 50 ng of prostaglandin E, after passing through the lung produced a response of the assay tissue equivalent to that produced by 5 ng given directly, inactivation was assessed as [(SO -5) 2.501 x 100 = 90%. The assay for arachidonic acid metabolites was slightly different as here there was activation of the substrate rather than inactivation. The amounts of arachidonic acid used when injected directly over the assay tissues did not cause them to contract, but when the same amounts had passed through the pulmonary vasculature, the rat stomach strip and rat colon were contracted. The 'rat stomach strip is responsive to most of the possible metabolites of arachidonic acid (thromboxanes, prostacyclin and prostaglandins) and thus the responses of this tissue were taken as a measure of overall production of the myotropic metabolites of arachidonic acid. The response was calibrated in terms of prostaglandin E, injected directly because this substance was a convenient and stable standard, even though the myotropic metabolites produced are a mixture of several, often unstable, metabolites.
The agonists under investigation were given either as injections (0.1-0.3 ml) or infusions (0.1-0.4 ml/min) into the flow of perfusate. Other agents, e.g. inhibitors, were infused at a constant rate (0.1-0.4 ml/min) into Krebs solution entering the lung for 10 rnin before and during the assay.
Frusemide was dissolved directly in Krebs solution to give the required concentration. Where inhibitors were used, each lung sample served as its own control, i.e. control metabolism was measured before inhibitor was infused.
Radiochetnical assays
In some experiments, 54°C lhydroxytryptamine and ['4C]phenylethylamine were infused for 3 rnin and the emuent was collected directly below the lungs either in timed fractions or in a single fraction over 30 min. By this time, radioactivity in the emuent had fallen to a low and constant level. EfRuent containing radioactivity from infusions of these amines was analysed on ionexchange resins by the method of Southgate & Collins (1969) .
After infusions of [ ''Clarachidonic acid (for 3 min at 0.4 ml/min), the emuent was collected in 1 min fractions or in a single fraction for another 7 min, i.e. 10 rnin in total, and the perfusion stopped. The lung sample was immediately removed from the perfusion apparatus, weighed and homogenized in 17 vol. of ice-cold chloroform/methanol (2: 1, v/v). The lung tissue was extracted and separated by coumn chromatography into phospholipid, neutral lipid and free fatty acid fractions (Jose & Seale, 1979) . The radioactivity associated with each fraction was measured.
Radioactivity in the efRuent was separated, after extraction, by thin-layer chromatography by using the methods described by Jose & Seale (1979) into cyclo-oxygenase products (including prostaglandins, thromboxanes, prostacyclin and their degradation products), hydroxy-fatty acids and arachidonic acid. Differences between means were considered significant if P < 0.05 as assessed by Student's 1-test for paired samples.
Results
With the bioassay, 5-hydroxytryptamine (injections of 100-500 ng of base, 5.7-28.5 nmol) was extensively inactivated (mean 71 f SE 4%, n = 17) on a single passage through the pulmonary vasculature of human lung and this inactivation was inhibited either by a tricyclic antidepressant, desmethylimipramine or by mebanazine, a monoamine oxidase inhibitor ( Table 1) . After the infusion of 5-[ ''C]hydroxytryptamine, 40% of the total radioactivity infused appeared in the efRuent in 15 rnin and, by 30 min, when a low and constant level of radioactivity had been attained, this proportion had increased to 70% (Fig. 1) . In the experiment shown, each fraction was separated into metabolite and unchanged amine. In others, a single 30 min fraction was collected and The values shown are the means (tse) of the number of experiments shown in parentheses. Inactivation of prostaglandin E, was measured by bioassay with injections of 100-500 ng (300-1500 pmol) of prostaglandin E, into the pulmonary vasculature. Significantly different from control value (P < 0.05).
Inactivation ( . through the pulmonary vessels, lung eRluent was collected in 0.5 min fractions for 4min, 1 rnin fractions for the next 6 min and 2 min fractions thereafter. Samples (1 ml) of each fraction were assayed for total radioactivity ( M), and, after ionexchange chromatography, for radioactivity due to 5-[14Clhydroxytryptamine metabolites ( 0---(3 (44 k 9%, n = 7) appeared in the emuent as metabolite over the 30 min period, and this proportion was decreased in the presence of desmethylimipramine ( Table 1) .
In three experiments, metabolism of phenylethylamine (0.25 pmol/l) was demonstrated radiochemically rather than by bioassay as this amine is much less potent on the rat stomach strip than 5-hydroxytryptamine (Vane, 1960) . The efRuent contained 48 2% metabolite with 91 f 7% of infused radioactivity emerging within 30 min.
The other substrates for pulmonary metabolism studied were prostaglandin E, and its precursor, arachidonic acid. Prostaglandin E, was extensively inactivated in a single passage through the human pulmonary vasculature and, furthermore, this inactivation was prevented by bromocresol green and frusemide ( Table 2 ). Analysis of emuent radioactivity by thin-layer chromatography showed several radioactive peaks (Fig. 2) . This range of radioactive products was divided into three areas, outlined by the dotted lines in Fig. 2 , which were defined as 'cyclooxygenase products', the area from prostaglandin F, to the ricinoleic acid marker, 'hydroxy-fatty acids', the area associated with the ricinoleic acid marker, 'and 'arachidonic acid', the area around the arachidonic acid marker. We did not seek to identify any particular peak in the cyclo-oxygenase products area with our marker prostaglandin FZp, E, and D , . From four such analyses, the proportion of emuent radioactivity chromatographing as cyclo-oxygenase products was 41 k 5% with 42 f 8% as unchanged arachidonic acid and only 5 & 1% in the hydroxy-fatty acid area.
Radioactivity retained in lung tissue at 10 min was present mostly in the phospholipid fraction with the smaller proportions in neutral lipid and free fatty acid fractions (Fig. 3) . No radioactivity associated with prostaglandin markers was found in lung extracts. 
Discussion
The pieces of human lung were used in the same way as we have previously used lungs from laboratory animals so that comparisons could be more easily made between species. The lack of high-molecular-weight solute in our perfusion fluid caused the accumulation of fluid in the tissue, but, over the time of the experiments (If h), this did not affect the variables we measured.
A similar stability of metabolism has been observed in our animal experiments.
Since our samples of lung were taken during operation, they could be considered as 'drugtreated' human lung rather than as 'normal' human lung, which we would like to study. In animal studies, anaesthetic gases in uiuo (Bakhle & Block, 1976) and in isolated lungs (Naito & Gillis, 1973) inhibited monoamine inactivation.
However, these effects were rapidly reversible and even the avidly bound drugs, imipramine (Junod, 1972) and propranolol (Dollery & Junod, 1976) , were lost from lung on perfusion with drug-free medium. We feel therefore that our samples of human lung in spite of their exposure to drugs in vivo were free of ,drugs by the time the experiments were carried out. Thus inactivation of 5-hydroxytryptamine and phenylethylamine and the inhibition of the former process in human lung were comparable with those reported already in a number of animal species (Alabaster, 1977) . In a series of investigations of amine metabolism in the human pulmonary circulation in viuo (Gillis et al., 1972) , 5-hydroxytryptamine was removed from blood by passage through the lung but the design of these studies in which blood was sampled for less than 1 min did not allow the ultimate fate of the removed 5-hydroxytryptamine to be determined. Our experiments suggest that 5-hydroxytryptamine taken up by human lung is subsequently metabolized, as it is in animals.
Inactivation of prostaglandin E, in isolated lung was high and comparable with that observed in patients (Jose et al., 1976; Hammond, Cronau, Whittaker & Gillis, 1977) . The effects of frusemide and bromocresol green showed that human lung is similar to rat lungs in terms of sensitivity to these two inhibitors (Bito & Baroody, 1975 ; Bakhle, 1979) .
The experiments with exogenous arachidonic acid show some interesting differences from the results obtained with guinea-pig lungs (Al-Ubaidi & Bakhle, 1979b). Thus, less activation (which probably represents less conversion into endoperoxide and F. Al-Vbaidi and Y. S. Bakhle thromboxane A,, because these a r e the metabolites of arachidonic acid most active on the rat stomach strip) was observed in human lungs than in guinea-pig lungs, where approximately 20 times more (20 ng of prostaglandin E, from 1 pg of arachidonic acid) activation was observed. If relatively more prostaglandin I, were produced in human lung, it might appear that less activation took place because the rat stomach strip is less sensitive to this metabolite of arachidonic acid (Gryglewski, Bunting, Moncada, Flower & Vane, 1976) . However, in the few experiments performed with the delay coil which were designed to detect, by the relaxation of the rat colon, the presence of prostaglandin I, (Alabaster & Hawkeswood, 1978) , such relaxations were not observed until comparatively high doses of arachidonic acid (5-10 pg) were injected. In guinea-pig lungs, for instance, relaxations of the rat colon could be seen with doses as low as 500 ng of arachidonic acid. We were not therefore able to show a proportionately higher amount of prostaglandin I, in human lung emuent by bioassay.
The experiments with [f4Clarachidonic acid confirmed this negative finding. First, only 10% of infused radioactivity emerged in human lung emuent after 10 min compared with 18% in 10 min in guinea-pig lung experiments. Secondly, over 30% of emuent radioactivity from human lung was unchanged arachidonic acid, whereas in guinea-pig lung the proportion was much lower (11%). If comparatively larger amounts of labelled prostaglandin I, were being produced in human lung, then the proportion of unchanged arachidonic acid should be lower than in guinea-pig lung effluent. It is therefore more likely that our samples of human lung exhibited a lower cyclo-oxygenase activity towards exogenous arachidonic acid in the pulmonary vasculature.
Another difference between guinea-pig and human lung was in the distribution of retained radioactivity (Al-Ubaidi, Bakhle, Jose & Seale, 1978) . Human lung had less label in phospholipid (46% vs 72%) and twice as much label present as free arachidonic acid (15% vs 7%). The latter result may be due to a higher phospholipase A, activity stimulated during homogenization of human lung even though the lungs were homogenized in cold chloroform/methanol mixtures. Alternatively, there may be a real species difference in the handling of exogenous arachidonic acid. Nevertheless, in both species there is an avid uptake of arachidonic acid from the pulmonary vessels and a rapid incorporation into phospholipid and neutral lipids.
In general, the samples of human lung exhibited metabolic properties qualitatively similar to those already established for animal lungs. We studied two types of substrate, monoamines and fatty acids, together so that we could obtain results more representative of the overall metabolic potential of our samples. Some of the properties have already been demonstrated in vivo but the isolated system we have used has some advantages. For instance, it has enabled us to investigate the inhibition of normal inactivation procesSes and the distribution of labelled substrates in lung tissue, investigations difficult to justify and perform in uivo. Furthermore, in our 'single-pass' perfusion system, there is no recirculation, a real problem in experiments carried out in uivo (Hammond et al., 1977) . Finally, the perfused human lung preparation provides an opportunity to test hypotheses to such a stage that confirmatory experiments in vivo become ethically possible. In spite of the possible differences between 'surgical' lung and normal lung, we believe that our results provide some insight into the pharmacokinetic functions of human lung.
